XGN | tickerfilter.com

Fundamental analysis

22%

Profitability 18%

Dept financing 14%

Liquidity 73%

Performance 16%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.70%

1 Month

27.16%

3 Months

66.13%

6 Months

171.05%

1 Year

202.94%

2 Year

110.20%

Key data

Stock price

$2.79

P/E Ratio

-2.99

DAY RANGE

$4.87 - $5.05

EPS

-$0.97

52 WEEK RANGE

$1.40 - $6.22

52 WEEK CHANGE

$202.94

MARKET CAP

51.811 M

YIELD

N/A

SHARES OUTSTANDING

17.386 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/11/2024

BETA

0.46

PUBLIC FLOAT

AVERAGE 10 VOLUME

$205,883

AVERAGE 30 VOLUME

$167,185

Company detail

CEO: John Aballi
Region: US
Website: exagen.com
Employees: 220
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases. Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases.

XGN - EXAGEN INC.